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Research Article
Utilising artificial intelligence to determine patients at risk of
a rare disease: idiopathic pulmonary arterial hypertension
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Abstract
Idiopathic pulmonary arterial hypertension is a rare and life-shortening condition often diagnosed at an advanced stage. Despite
increased awareness, the delay to diagnosis remains unchanged. This study explores whether a predictive model based on
healthcare resource utilisation can be used to screen large populations to identify patients at high risk of idiopathic pulmonary
arterial hypertension. Hospital Episode Statistics from the National Health Service in England, providing close to full national
coverage, were used as a measure of healthcare resource utilisation. Data for patients with idiopathic pulmonary arterial hyper-
tension from the National Pulmonary Hypertension Service in Sheffield were linked to pre-diagnosis Hospital Episode Statistics
records. A non-idiopathic pulmonary arterial hypertension control cohort was selected from the Hospital Episode Statistics
population. Patient history was limited to 5 years pre-diagnosis. Information on demographics, timing/frequency of diagnoses,
medical specialities visited and procedures undertaken was captured. For modelling, a bagged gradient boosting trees algorithm
was used to discriminate between cohorts. Between 2008 and 2016, 709 patients with idiopathic pulmonary arterial hypertension
were identified and compared with a stratified cohort of 2,812,458 patients classified as non-idiopathic pulmonary arterial hyper-
tension with 1 ICD-10 coded diagnosis of relevance to idiopathic pulmonary arterial hypertension. A predictive model was
developed and validated using cross-validation. The timing and frequency of the clinical speciality seen, secondary diagnoses and age
were key variables driving the algorithm’s performance. To identify the 100 patients at highest risk of idiopathic pulmonary arterial
hypertension, 969 patients would need to be screened with a specificity of 99.99% and sensitivity of 14.10% based on a prevalence
of 5.5/million. The positive predictive and negative predictive values were 10.32% and 99.99%, respectively. This study highlights the
potential application of artificial intelligence to readily available real-world data to screen for rare diseases such as idiopathic
pulmonary arterial hypertension. This algorithm could provide low-cost screening at a population level, facilitating earlier diagnosis,
improved diagnostic rates and patient outcomes. Studies to further validate this approach are warranted.
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Introduction
Idiopathic pulmonary arterial hypertension (iPAH) is a rare,
progressive and life-shortening disease. It is characterised by
a small vessel vasculopathy and elevated pulmonary artery
pressure; and if it is untreated, it leads to right heart failure
and death, with a median survival of less than three years.1
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The annual incidence of iPAH has been estimated at 1–3.3
cases per million per year.2–4 Estimates of UK prevalence of
idiopathic, heritable or anorexigen-induced PAH range from
12.4 to 24.8 per million,5 with recent published data from the
national audit, identifying a prevalence of 15 per million of
population in England.6 The symptoms of iPAH are non-
speciﬁc and clinical signs are subtle until the disease is
advanced. Progressive shortness of breath and fatigue are
common; and as the disease progresses, exertional chest tight-
ness, pre-syncope and syncope may occur. Leg swelling is a
late sign in young patients and reﬂects severely impaired right
ventricular function.7 Given the rarity of iPAH and the non-
speciﬁcity of symptoms, patients are frequently misdiagnosed
with other common cardiorespiratory diseases. A lengthy
delay between the onset of symptoms and a deﬁnitive diag-
nosis is normal, typically around two years; and this delay is
unchanged over the last two decades.8Consequently, iPAH is
often diagnosed at an advanced stage in terms of symptom
burden and haemodynamic severity.9 In contrast, systemic
sclerosis-associated pulmonary arterial hypertension (SSc
PAH) is typically diagnosed earlier, as the high prevalence
(9%) of PAH in SSc has led to the implementation of speciﬁc
screening programmes in this high-risk group of
patients.10–12 Furthermore, an evidence-based algorithm for
early SSc PAH detection has recently been developed.13
The application of artiﬁcial intelligence (AI) capabilities,
and speciﬁcally machine learning algorithms, has created the
opportunity to identify actionable healthcare insights from
large and complex healthcare datasets.14,15 One proposed
application of such technologies is to use routinely collected
patient data to screen for or predict those at high risk for
disease to potentially improve patient outcomes.16 Examples
of such data include the National Health Service (NHS)
Hospital Episode Statistics (HES) database in England,
which provides close to full national coverage for a popula-
tion of approximately 55 million, and medical insurance
records in the United States, where coverage varies depend-
ing on provider and/or location.
Recently, we published data from the Sheﬃeld
Pulmonary Hypertension IndeX (SPHInX) project, demon-
strating that patients with iPAH have high levels of health-
care resource utilisation (HCRU) in the three years prior to
diagnosis, with approximately 25 hospital visits.17 We also
demonstrated that national HES data can be linked to
patient-level hospital diagnostic data in patients with
iPAH in 99% of cases. Our analyses showed that HES
data has the potential to support the development of a pre-
dictive model to screen for iPAH.17 In this study, we now
describe the development and internal validation of a pre-
dictive AI model to identify patients at risk of iPAH.
Methods
Construction of the SPHInX dataset
To identify HCRU patterns in the years prior to a diagnosis
of iPAH, we obtained NHS HES patient records from April
2000 to March 2017 for all patients diagnosed with iPAH at
the Sheﬃeld Pulmonary Vascular Disease Unit (SPVDU)
during 2008–2016. These HES data consisted of information
relating to inpatient, outpatient and accident and emergency
attendances. For a non-iPAH group, we identiﬁed a cohort
of patients using codes from the 10th revision of the
International Statistical Classiﬁcation of Diseases and
Related Health Problems (ICD-10) that were associated
with cardiorespiratory disease and frequently used in
patients with iPAH.
NHS numbers were used to link the HES datasets with
positive iPAH cases diagnosed at SPVDU. A diagnosis of
iPAH was conﬁrmed by medical expert, and the study
included only those that had undergone detailed clinical
assessment including blood testing, lung function testing,
exercise testing, echocardiography, multi-modality imaging
(nuclear medicine imaging, computed tomography, mag-
netic resonance imaging), right heart catheterisation and
classiﬁcation according to international guidelines and
multidisciplinary assessment.18 Patient linkage was quality
controlled by comparing the consistency of gender, year of
birth, general practitioner postcode and key dates (ﬁrst diag-
nosis, ﬁrst right heart catheterization and ﬁrst visit at
SPVDU). The initial non-iPAH cohort included all HES
patients who had at least one primary or secondary diagno-
sis in ICD-10 codes relevant to cardiorespiratory disease,
that would result in high levels of HCRU similar to iPAH
but whose pattern of behaviour would ideally be distin-
guishable from iPAH. The list of pre-speciﬁed ICD-10
codes for the deﬁnition of the non-iPAH cohort can be
found in Supplementary Table 1.
Selection of clinical variables for inclusion in the
predictive model
We considered diagnoses (ICD-10 coding scheme), proced-
ures codes (OPCS coding scheme) and the clinical specialty
of the treating physician (‘clinical specialty’ codes) as poten-
tial variables for the predictive model. Diagnosis and pro-
cedure codes were labelled as either primary or secondary in
the HES dataset; primary diagnosis referred to the main
condition investigated, and primary procedure referred to
the most resource-intensive procedure carried out. All
other diagnoses and procedures contained within the epi-
sode were captured as secondary.
To select a set of diagnosis and procedure codes relevant
to the iPAH HCRU footprint, a hybrid data- and clinically
driven approach was used. First, all codes that appeared in
1% of the iPAH cohort (condition 1) or <1% of the iPAH
cohort and >2% of the non-iPAH cohort (condition 2) were
selected. The non-iPAH cohort in this selection step com-
prised 5630 patients conﬁrmed to not have iPAH who
attended SPVDU within the study window. This method
ensured that variables found rarely in the iPAH cohort
but more commonly in non-iPAH were retained for model-
ling (i.e. the anti-correlated events). To reduce the number
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of variables further, variables were included only if they
were: (i) deﬁnitely or possibly related to the iPAH journey
(for those identiﬁed by condition 1) and (ii) deﬁnitely or
possibly relevant to the exclusion of iPAH (for those identi-
ﬁed by condition 2), following independent review by two
clinical experts. For inclusion, a variable had to be selected
by at least one of the experts. The experts were blinded to
the prevalence of the codes. All clinical specialty codes
appearing in at least 1% of the iPAH cohort were included
in the model.
The selected variables were described using three metrics;
frequency variables (e.g. the frequency of certain proced-
ures), date diﬀerence variables (e.g. the number of days
between a procedure and the index date) and aggregated
time variables (e.g. the number of new diagnoses within 12
months of the index date). Clinical codes or events that were
missing were assumed to represent an absence of the event
and were encoded as a zero for count metrics. Data diﬀer-
ence metrics for absent events were coded as missing and
passed to the model directly.
Definition of index date and lookback period for devel-
opment of predictive model
In this study, the pre-diagnosis history window was limited
to a maximum of ﬁve years from the index date
(Supplementary Fig. 1). For the non-iPAH cohort, the
index date corresponded to the most recent relevant event
in the patient’s history. An event was considered relevant if
it – (i) contained a diagnosis code belonging to the list of
pre-speciﬁed ICD-10 codes relevant to iPAH and (ii) was a
cardiology, respiratory or neurology clinical specialty. For
the iPAH cohort, the index date was the most recent rele-
vant event prior to the ﬁrst visit at the SPVDU, ensuring
that the pre-diagnosis history occurred prior to their referral
to SPVDU and hence substantially prior to the date of con-
ﬁrmed diagnosis. Patients in both cohorts without a valid
index date were excluded. The lookback period was deﬁned
as either ﬁve years or the entire length of a patient’s history
in the HES records, which ever was shortest.
Selection of population for development of
predictive model
To build a robust predictive model for iPAH, it is crucial to
ensure that the non-iPAH cohort is comprised of patients
who have similar patterns of HCRU in the years leading up
to diagnosis. That is, we want to ensure that the predictive
model is being trained to learn an iPAH HCRU footprint
rather than merely distinguishing patients who have low
versus high HCRU. Stratiﬁcation was applied to narrow
the non-iPAH cohort to patients who more closely resemble
patients with iPAH. Each patient was required to have at
least one of the selected ICD-10 codes (see ‘Selection of
clinical variables for inclusion in the predictive model’) in
the primary diagnosis ﬁeld.
AI methodology underpinning the predictive model
For rare disease detection based on historical HCRU, a pre-
dictive model design should be sensitive to interactions
between HCRU events and avoid overﬁtting while lever-
aging the richness of the data available (Supplementary
Fig. 2). To accommodate this, we utilised gradient boosting
trees, a supervised machine learning algorithm, to develop
our predictive model.19 This algorithm is an ensemble of
decision trees implemented using boosting, whereby the suc-
cessive tree aims to reduce the error of the previous tree. The
algorithm was embedded within a bootstrap aggregation
framework whereby 100 base learners were trained on a
bootstrapped sample of the training dataset where sampling
was carried out with replacement.20 The scores of all the
learners were averaged to produce the prediction on the
test set.20 The base learner of the model was implemented
using the XGBoost package.21 Each gradient boosting tree
model was a combination of 50 trees. All other XGBoost
parameters were set to default values. XGBoost handles
missing data by learning which branch of the node (pertain-
ing to the missing variable) is optimal for a given observa-
tion. The analysis was performed on a local Dell PowerEdge
R730xd Server with 2 Intel Xeon E5-2695 v3 2.3GHz pro-
cessors and 64Gb LRDIMM 2400MT/s RAM. Fig. 1(a)
provides an overview of the key steps in the algorithm’s
development.
Validation of the predictive model
To assess model performance, data were partitioned into
training and test sets. Training data were used to learn the
parameters of the model while test data were used to esti-
mate how well the model would generalise to new patients.
Given the relatively small number of patients with iPAH
available, a cross-validation strategy was used to assess
model performance while providing predictions for all
patients included in modelling.22 Speciﬁcally, a ﬁve-fold
cross-validation was used (Fig. 1(b)), in which patients
were partitioned into ﬁve non-overlapping groups. Four
groups were used for training of the model and the ﬁnal
group was used for testing. This process was iterated using
each group served as a test set.
The contribution of each variable to the performance of
the individual gradient boosting tree model was averaged
across all learners in the bagged ensemble to provide a
single view of variable importance. The output of the
model, a risk score assigned to each patient that ranges
from 0 to 1, was compared with a determined threshold to
categorise patients predicted as iPAH-positive or iPAH-
negative.
The performance metrics for the predictive model were
based on conservative estimates of prevalence of iPAH from
published data.23,24 Rates of 1/1,000,000 (lower bound), 5.5/
1,000,000 (middle) and 10/1,000,000 (upper bound) were
used. These prevalence estimates provide guidance for how
to scale the expected count of false positives in a real-world
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clinical setting. Sensitivity (true positives/(true posi-
tivesþ false negatives)) and speciﬁcity (true negatives/(true
negativesþ false positives)) were calculated. Positive pre-
dictive values (PPV) and negative predictive values (NPV)
were calculated for the three levels of stratiﬁed prevalence
whereby the count of false positives was projected to the
level expected to be observed at a stratiﬁed population
level. That is, performance metrics were scaled so that
they are representative of what would be expected in a
real world clinical setting. The likelihood of a positive test
(sensitivity/(1 – speciﬁcity)) was calculated as a measure of
how frequently a positive diagnosis prediction is made for
those with compared with iPAH versus those without iPAH.
Results
Sample population
Fig. 2 summarises the sampling strategy used to identify
patients within the iPAH and non-iPAH cohorts. A total
of 864 patients with a conﬁrmed iPAH diagnosis at the
SPVDU were initially identiﬁed. A comparison of the
SPVDU and HES datasets revealed that 13 patients had
duplicate database IDs, resulting in an initial group of 852
patients in the iPAH cohort. After application of the strati-
ﬁcation criteria, designed to ensure that the variable distri-
butions of the two cohorts closely resembled one another,
this was reduced to 750 patients. The initial non-iPAH
cohort consisted of 11,354,750 patients, and was reduced
to a cohort of 2,952,235 patients after application of the
stratiﬁcation criteria. Patients without a valid index date
or at least one month of history prior to the index date
were removed, resulting in 709 and 2,812,458 patients
within the iPAH and non-iPAH cohorts, respectively. The
demographics for the iPAH and non-iPAH cohort are
shown in Supplementary Table 2, and the baseline pheno-
typic characteristics of patients with iPAH in
Supplementary Table 3. Patients with iPAH had a lower
median age (60 years versus 71 years) and had a lower
rate of systemic hypertension (48% versus 60%) than
Fig. 2. Sampling strategy to select patients for the iPAH and non-iPAH cohorts used in the modelling procedure. Stratification of the non-iPAH
cohort was used to narrow the cohort to patients who more closely resemble those with iPAH.
HES: Hospital Episode Statistics; ICD-10: International Statistical Classification of Diseases and Related Health Problems, 10th Revision; iPAH:
idiopathic pulmonary arterial hypertension; SPVDU: Sheffield Pulmonary Vascular Disease Unit.
(a) (b)
Fig. 1. (a) The bagging approach adopted in the predictive model. Each learner of the bagged ensemble is a gradient boosting tree model
composed of 50 trees (N¼ 100). (b) Cross-validation strategy used for the training and the test of the model performance. This strategy has been
preferred to a single hold-out set due to the modest size of the iPAH cohort.
iPAH: idiopathic pulmonary arterial hypertension.
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those without iPAH. For the iPAH cohort, the average time
between the ﬁrst visit at SPVDU and the index date was
76 272 d.
Clinical variables for inclusion in the predictive model
Following variable selection, a total of 141 clinical variables
were initially identiﬁed for inclusion in the model: 23 pri-
mary diagnoses, 74 secondary diagnoses, 24 primary proced-
ures and 19 secondary procedures, plus the age at the index
date (see Supplementary Table 4). After an initial analysis,
the ICD-10 codes I270 (primary pulmonary hypertension)
and I272 (other secondary pulmonary hypertension) were
excluded from the model variables. These predictors are
strongly related to receiving a subsequent diagnosis of
iPAH and could therefore artiﬁcially inﬂate the performance
of the model, and are typically coded for patients shortly
before their referral to tertiary care for the iPAH cohort.
A total of 142 clinical specialty codes were contained in the
two cohorts; of these, the 52 clinical specialty codes (see
Supplementary Table 5) appearing in at least 1% of the
iPAH cohort were included as variables in the model.
Validation of the predictive model
In Fig. 3(a), the PPV is plotted as a function of sensitivity
and speciﬁcity at three diﬀerent levels of iPAH prevalence.
Fig. 3(b) shows the PPV and NPV as a function of iPAH
prevalence. Assuming an iPAH prevalence of 5.5:1,000,000,
the predictive model would need to screen 969 patients to
identify 100 patients with iPAH. At a prevalence of
10:1,000,000, the number of patients required to identify
the 100 patients with iPAH would drop to 587. Based on
the conservative prevalence estimate of 5.5 per million, the
Fig. 3. (a) PPV as a function of sensitivity (left) and specificity (right) for different levels of prevalence. (b) PPV and NPV as a function of iPAH
prevalence per million in the full population when the model is optimized to find 100 patients with iPAH.
iPAH: idiopathic pulmonary arterial hypertension; NPV: negative predictive value; PPV: positive predictive value.
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model has 99.99% speciﬁcity, 14.10% sensitivity with
10.32% PPV and 99.99% NPV. This corresponds to a like-
lihood ratio of a positive test of 1151. A 2 2 contingency
table of the model when optimized to identify 100 true posi-
tive patients with iPAH is shown in Table 1. To contextual-
ise these results, the stratiﬁed population with this
conservative estimate of prevalence in the absence of the
predictive model would be expected to contain one patient
with iPAH in every 10,000 screened. This corresponds to a
PPV of 0.01%, as compared with a PPV of 10.32% for the
predictive model.
The speciﬁcity and sensitivity of the model vary accord-
ing to the risk score threshold used to determine whether a
patient is classiﬁed as iPAH or non-iPAH. This threshold
can be lowered in order to identify higher numbers of
patients with iPAH. Similarly, the less prevalent the disease,
the more patients that must be screened to identify the same
number of true positive patients with iPAH. A detailed
breakdown of the number of positively-identiﬁed patients
who would need to be screened to identify a certain
number of patients with iPAH is shown in Table 2.
Fig. 4 shows the top 15 most important variables for
model performance. The timing and frequency of the clin-
ical speciality seen, the burden of co-morbidities and
patient age were found to be the key variables driving
the performance of the algorithm. To evaluate whether
the model is selecting patients for clinically meaningful
patients for iPAH screening, we examined the proﬁles of
the top 100 patients with iPAH predicted as such by the
model (i.e. the true positives: patients with iPAH and the
highest scores) and the top 500 non-iPAH patients pre-
dicted as iPAH (i.e. the false positives; patients receiving
high score that are not aﬀected by the disease)
(Supplementary Table 6). We observed similar frequencies
of physician clinical specialties across these two groups,
particularly for Respiratory Medicine, Cardiology and
General Medicine. The top false positives were observed
to have similar or higher proportions of patients with sec-
ondary ICD codes. This suggests that the false positives
identiﬁed by the model are indeed patients that experience
a pre-diagnosis HCRU footprint similar to that of patients
with conﬁrmed iPAH.
Discussion
To our knowledge, this is the ﬁrst study to describe an AI
approach using routinely collected data on HCRU to
develop a screening algorithm to identify patients at high
risk of iPAH. Key variables for model performance were
the timing and frequency of clinical specialities, secondary
diagnoses and procedures. The promising results reported in
this study indicate the potential role for the application of
AI to routinely collected healthcare data for population
health screening in iPAH and other rare diseases.
The screening algorithm has been developed through
numerous iterative steps by a multi-disciplinary team,
including clinical and AI experts, and speciﬁcally to account
for the epidemiology and confounding conditions related to
diagnosing iPAH. We have also accounted for the diagnos-
tic service model for iPAH in the NHS in England, which is
delivered by a network of specialist pulmonary hypertension
centres; this is reﬂected in the iPAH population index date
deﬁnition (i.e. only using patient data prior to referral to a
specialist centre for modelling).
In the present study, to identify 100 patients with iPAH
(true positives), 969 patients identiﬁed by the model as being
at a high risk of iPAH would be needed to be screened
(based on a prevalence of 5.5 per million). This corresponds
to a speciﬁcity of 99.99%, a sensitivity of 14.10%, PPV of
10.32% and NPV of 99.99%. The likelihood ratio of a posi-
tive test is 1151, meaning that the model would identify a
patient as being at a high risk of iPAH 1151 times more
often in patients who do have iPAH than in patients who
do not. These performance metrics represent a conservative
Table 2. Performance of the model. The performance of the model
is expressed in terms of patients who would need to be screened
(patients identified as positive by the model) in order to find a certain
number of patients with iPAH (true positive patients). The number of
patients to be screened also depends on the population/stratified
prevalence of the disease, as indicated in the heading rows.
Number of model-identified
patients to screen for iPAH
Stratified prevalence: 1:5600 1:10,000 1:56,000
Population prevalence: 10:1m 5.5:1m 1:1m
iPAH Patients Identified
10 44 70 346
25 109 175 864
50 212 340 1672
75 383 624 3151
100 587 969 4965
200 1911 3256 17,312
250 3163 5453 29,385
300 5970 10,426 57,004
350 9616 16,897 93,011
400 19,189 33,953 188,295
iPAH, idiopathic pulmonary arterial hypertension; m, million.
Table 1. A 2 2 contingency table of the model output when opti-
mised to find 100 patients with iPAH. It is assumed that the prevalence
of the disease in the stratified population is 1:10,000.
Predicted:
non-iPAH
Predicted:
iPAH Total
Actual: non-iPAH TN¼ 7,089,131 FP¼ 869 7,090,000
Actual: iPAH FN¼ 609 TP¼ 100 709
7,089,740 969
FN: false negative; iPAH: idiopathic pulmonary arterial hypertension; TN: true
negative; FP: false positive; TP: true positive.
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view of the likely prevalence of iPAH in England. For the
purpose of this study, we focussed on the lower bound of
prevalence found in the published literature (5–6 cases per
million18), whereas in England national audit data have
indicated a prevalence of 15 per million.6 As we demon-
strate, the performance of the model would improve with
increased prevalence levels; and based on a prevalence of 10
per million, 587 patients ﬂagged as being at high risk by the
model would need to be screened to identify 100 patients
with iPAH.
We acknowledge that the PPV of 100 per 969 (10.32%)
may appear to be low; however, this represents a signiﬁcant
step change when compared with the estimated prevalence
of iPAH. This algorithm therefore identiﬁes patients for
screening for iPAH at much higher rate than the back-
ground prevalence by a factor of 10,000. Indeed, the per-
formance of this algorithm is similar to the prevalence of
PAH in SSc. The beneﬁts of using screening algorithms to
identify patients with iPAH has been demonstrated in con-
text of SSc using the DETECT screening algorithm.13 In
contrast with iPAH, where the prevalence of disease is low
in the general population, PAH occurs in approximately 9%
of patients with SSc.12 The DETECT model has been
demonstrated to eﬀectively diagnose patients with SSc
PAH in a clinical setting, showing that a targeted approach
that identiﬁes patients at high risk of a rare diseases is feas-
ible.13 Evidence suggests that earlier treatment is associated
with improved outcomes in patients with iPAH25–27; and in
SSc PAH, a comparison of contemporaneous cohorts of
patients diagnosed from screening versus symptomatic pres-
entation demonstrated that those patients identiﬁed from
screening had less severe haemodynamic disease and better
survival.28 A criticism of these studies is the potential for
lead time bias to inﬂuence outcomes, and no studies in PAH
have unequivocally demonstrated that earlier intervention
alters the natural history of disease.29 Given the success of
PAH screening in SSc, even at current performance, the
model would identify patients for screening at a manageable
level, where investigative approaches to diagnose pulmonary
hypertension could be deployed.
In contrast with SSc, iPAH has no known associated risk
factors that would facilitate such an accurate predictive
model. However, patients with iPAH do have high levels
of HCRU prior to diagnosis, with recent work by our
group identifying an average of 25 hospital interactions in
the three years prior to diagnosis.17 The present study dem-
onstrates that we can identify patients with a high risk of
iPAH at a similar rate to that of PAH in patients with SSc.
The current economic burden of iPAH is high, with patients
presenting with more severe disease requiring more inpatient
admissions, longer lengths of stay and more emergency
department visits.17,30 As the SPHInX predictive model is
based upon existing, accessible and routinely-collected
healthcare data, the cost of identifying patients at high
risk of iPAH would be relatively small, and could therefore
be of value despite the low sensitivity for iPAH. However,
the health economic impact of investigating patients identi-
ﬁed at high risk of iPAH and approaches to contacting these
patients would require further exploration. Developing pre-
dictive models that identify patients at high risk of speciﬁc
diseases using routinely collected HCRU data provides an
opportunity to design studies that can explore the health
economic impact of diagnostic and treatment interventions
in these high-risk patients. This would allow the
Fig. 4. The 15 most important variables of the model, ranked by average rank across the 100 bags and five groups. The importance of the
variables is expressed in terms of a normalized value between 0 and 1 that corresponds to how much each variable contributes to the
performance of the gradient boosting tree. Each colour corresponds to the variable class (see key).
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development of novel study designs randomising high-risk
patients to integrated diagnostic and treatment strategies
that would allow a comprehensive health technology assess-
ment. In addition, this would facilitate a comparison of
long-term outcomes eliminating the potential lead time
bias of historic studies comparing earlier treatment interven-
tions in unmatched cohorts.
This study has a number of limitations. First, iPAH is a
rare condition and the methodological approach used due to
the number of patients meant that we used a cross-valida-
tion approach rather than having separate training and test
cohorts. Second, the HES dataset is an example of a system
that records secondary care HCRU from a national cohort;
but the data ﬁelds and type of activity that are recorded are
speciﬁc to this system. However, the general principles
underpinning these datasets are similar to those used in
other countries and the concept is therefore potentially
translatable, but requires further validation. Finally, the
performance of any predictive model depends on the popu-
lation in which the model is deployed. However, one of the
beneﬁts of using an AI approach is the ability of the model
to learn and be adapted based on the characteristics of the
population studied. Although the algorithm was developed
on an English population, conﬁrmed iPAH cases were
obtained from a single UK centre. However, the Sheﬃeld
centre provides population coverage for over 15 million
people,9,17 representing approximately one-third of the
English population, and the 864 patients identiﬁed over a
16-year period equates to an estimated annual incidence of
3.6 per million per year and an estimated prevalence of 19
per million, in keeping with the published national data. The
conﬁrmed iPAH cases were also demographically similar to
that reported in other registries.
In conclusion, this study highlights the potential applica-
tion of AI using existing and routinely collected data to
identify patients at high risk of rare conditions such as
iPAH. Studies to further validate this approach to screen
for iPAH in the general population are now warranted.
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